How can we help you?

CORPORATE HEADQUARTERS

Biogen Inc.
225 Binney Street
Cambridge, MA 02142
USA

Biogen Corporate Contacts

INTERNATIONAL HEADQUARTERS

(Europe & Canada)
Biogen International GmbH
Neuhofstrasse 30
6340 Baar
Switzerland

Media

EU Media Enquiries
publicaffairs.eu@biogen.com

U.S. Public Affairs/Media
+1 781 464 3260
public.affairs@biogen.com

Investors

Visit our Investors page for financial information and reporting.

Investor Relations
+1 781 464 2442
IR@biogen.com

Patient safety is our highest priority and we are committed to completing timely evaluation of benefits and risks of our therapies and communicating this information to help healthcare professionals and patients make informed treatment choices.

Biogen has an ethical and regulatory responsibility to continually assess and communicate the benefit/risk profile of our products to patients, healthcare professionals and regulators.

On an ongoing basis, we collect information regarding adverse events and other safety information from patients, caregivers and healthcare professionals, among others. Additionally, in some instances, we conduct post-marketing studies to evaluate therapies’ long-term effects.

Our safety and benefit risk management team reviews safety information received from all sources (foreign, domestic, clinical trials, published literature, post-marketing) for our products and determines what actions, if any, may need to be taken regarding any potential evolving safety profile of our products.

When a potential safety issue is identified, we seek information to better understand the issue and we report our findings to applicable regulatory agencies. We also communicate newly identified product safety information to healthcare professionals and patients by updating the product labelling and providing other communications, as appropriate.

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard, or search for MHRA Yellow Card or in the Google Play or Apple App Store (UK) or www.hpra.ie or by email to medsafety@hpra.ie (Ireland). By reporting side effects, you can help provide more information on the safety of this medicine. 

We encourage patients and healthcare professionals to report adverse events to Biogen (contact details below) or to the national regulatory agency. Please note in order to meet our ethical and regulatory obligations mentioned above, we may need to contact you to obtain further details regarding the adverse event. For any adverse events reported to us we are obliged to store certain details about the you the reporter, the patient (if different to the reporter) and details relevant to the adverse event as well as report on to regulatory agencies globally. Please refer to Biogen’s Privacy Policy for further details.

Biogen UK and Ireland contact details:
For neuroscience products UK 0800 008 7401 | IRE 1800 812 719 | Email: MedInfoUKI@biogen.com
For biosimilar products UK 0203 608 8622 | IRE 01 513 33 33 | Email: Medinfo.europe@biogen.com

Note: Biogen markets Biosimilar products pursuant to an agreement with Samsung Bioepis, the marketing authorisation holder for such products. If you report an Adverse Event (AE) / Product Complaint (PC) for any of these products, your report will be sent to Samsung Bioepis, who may follow-up with you if they require further information regarding your AE or PC.

If you wish to report any compliance concerns regarding Biogen or any of its employees or contractors, you may do so in writing at the address provided below or confidentially and anonymously, by using the Compliance Helpline.

To submit a report through the Compliance Helpline, click here for international Compliance Helpline dial-in numbers.

Click here to submit a report online, or write to us at:

Compliance
Biogen International GmbH
Neuhofstrasse 30
6340 Baar
Switzerland